However, the objective response rate was the lowest among entrectinib‐treated NTRK+ colorectal cancer (CRC) (20%) and selpercatinib‐treated RET+ CRC (20%) among all NTRK+, and RET+ solid tumors, respectively. This evidence concerns the gene RET and colorectal carcinoma.